CSIMarket
 
Citius Oncology Inc  (NASDAQ: TENKU)
 
Price: $0.0000 $0.00 %
Day's High: 0.00 Week Perf:
Day's Low: $ 0.00 30 Day Perf:
Volume (M): 0 52 Wk High: $ 0.00
Volume (M$): $ 0 52 Wk Avg: $0.00
Open: $0.00 52 Wk Low: $0.00



 Market Capitalization (Millions $) -
 Shares Outstanding (Millions) 108
 Employees -
 Revenues (TTM) (Millions $) 3
 Net Income (TTM) (Millions $) -46
 Cash Flow (TTM) (Millions $) -1
 Capital Exp. (TTM) (Millions $) 8

Business Description


Tenx Keane Acquisition is a merger between Tenx Capital, a private equity firm, and Keane, a leading provider of comprehensive solutions for unclaimed property compliance and investigations. The acquisition aims to combine their respective expertise and resources to create a stronger entity in the unclaimed property industry.

Tenx Capital brings its financial expertise and capital resources to the partnership, while Keane brings its extensive experience and established presence in the field of unclaimed property compliance. Through this merger, the companies seek to expand their capabilities, enhance their service offerings, and create a larger market presence.

The acquisition is expected to drive growth for both parties by leveraging their synergies and expanding their customer base. It also offers an opportunity to develop innovative solutions and advanced technologies to better serve clients in managing and resolving unclaimed property obligations.

Overall, the Tenx Keane Acquisition aims to create a market leader in the unclaimed property industry by combining the strengths and capabilities of Tenx Capital and Keane.


   Company Address: 420 Lexington Ave New York 10170 NY
   Company Phone Number: 627-0058   Stock Exchange / Ticker: NASDAQ TENKU


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   





Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) -
Price to Sales (Expected) -
Price to Book -
PEG (TTM) -

Financial Strength Current
Quick Ratio 0.5
Working Capital Ratio 1.29
Leverage Ratio (MRQ) 1.78
Total Debt to Equity 0.41
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) -0.5 $
Revenues (TTM) 0.03 $
Cash Flow (TTM) -
Cash 0.15 $
Book Value 0.37 $
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) -
Net Income per Employee (TTM) -
Receivable Turnover Ratio (TTM) 7.16
Inventory Turnover Ratio (TTM) 0.04
Asset Turnover Ratio (TTM) 0.03

Profitability Ratios Current
Gross Margin (MRQ) 67.07 %
Operating Margin (MRQ) -583.54 %
Net Margin (MRQ) -597.4 %
Net Cash Flow Margin (MRQ) 0 %
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -



Citius Oncology Inc's Segments





Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.